Miscellaneous and experimental agents

American Journal of the Medical Sciences

Volumn 313, Issue 1, 1997, Pages 33-40

  Reginster, Jean Yves ^a,b,c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b GEORGETOWN UNIVERSITY   (United States)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Anabolic steroids; Growth hormone; Osteoporosis; Parathormone; Strontium

Indexed keywords

ANABOLIC AGENT; ANTIESTROGEN; ECHISTATIN; GROWTH HORMONE; IPRIFLAVONE; PARATHYROID HORMONE; SOMATOMEDIN; STRONTIUM;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE REMODELING; BONE STRUCTURE; DRUG EFFECT; DRUG SAFETY; FEMALE; HIP FRACTURE; HUMAN; OSSIFICATION; OSTEOLYSIS; PARATHYROID FUNCTION; POSTMENOPAUSE OSTEOPOROSIS; TREATMENT PLANNING; VIRILIZATION;

EID: 0031031380     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199701000-00006     Document Type: Article

References (111)

1. Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis. JAMA, 1941;6:2465-74.
2. Reifenstein EC, Albright F. The metabolic effects of steroids hormones in osteoporosis. J Clin Invest, 1947;26:24- 56.
3. Kopera H. The history of anabolic steroids and a review of clinical experience with anabolic steroids. Acta Endocrinol (Copenh). 1985;S10:118.
4. Taggart HA, Applebaum-Bowden D, Haffner S, et al. Reduction in high density lipoproteins by anabolic steroid (stanazolol) therapy for postmenopausal osteoporosis. Metabolism. 1982;3:1147-52.
5. Ishak KG, Ziminerman HJ. Hepatotoxic effects of the anabolic/androgenic steroids. Semin Liver Dis. 1987;7:230-6.
6. Wilson J, Griffin JE. The use and misuse of androgens. Metabolism. 1980;29:1278-95.
7. Geusens P. Nandrolone decanoate: Pharmacological properties and therapeutic use in osteoporosis. Clin Rheumatol. 1995;14:32-9.
8. Kasperck CH, Wergedal JE, Farley JR, et al. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology. 1989;124:1576-8.
9. Riggs BL. Formation-stimulating regimens other than sodium fluoride. Am J Med. 1993;95:S62-S68.
10. 3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double- blind controlled study. Bone Miner. 1986;1:347-57.
11. Hassager C, Podenphant J, Riis BJ, Johansen JS, Jensen J, Christiansen C. Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic women. Metabolism. 1989;38:238-42.
12. Need AG, Horowitz M, Morris HA, Walker CJ, Nordin BEC. Effects of nandrolone therapy on forearm bone mineral content in osteoporosis. Clin Orthop. 1987;225:273-8.
13. 3, or intermittent calcium infusions. Maturitas. 1986;8:281-9.
14. Kanis JA, Johnell O, Gullberg B, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. Br Med J. 1992;305:1124-8.
15. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet. 1992;339:71-85.
16. Powels TJ. The case for clinical trials of tamoxifen for prevention of breast cancer. Br J Cancer. 1992;60:126-31.
17. Fugh-Berman A, Epstein S. Should healthy women take tamoxifen? N Engl J Med. 1992;327:1596-7.
18. Turner RT, Wakley GK, Hannon KS, Bell NH. Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology. 1988;122:1146-50.
19. Turner RT, Wakley GK, Hannon KS, Bell NH. Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Miner Res. 1987;2:449-56.
20. Love RR, Barden HS, Mazess RB, Epstein S, Chappell RJ. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med. 1994;154:2585-8.
21. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326:852-6.
22. Kristensen B, Ejlertsen B, Dalgaard P, et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer partients: A randomized study. J Clin Oncol. 1994;12:992-7
23. Love RR, Newcomb PA, Wiebe DA, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node negative breast cancer, J Natl Cancer Inst. 1990;82:1327-32.
24. Neven P, De Muylder X, Van Belle Y, Campo R, Vanderick G. Tamoxifen and the uterus. Br Med J. 1994; 309:1313-4.
25. Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol. 1994;47:827-33.
26. Jones CD, Jevnikar MG, Pike AJ, et al. Antiestrogens, 2. structure-activity studies in a series of 3-aroyl-2 arylbenzo[b]thiopene derivatives leading to [6-hydroxy-2-(4- hydroxy-phenyl)benzo[blthien-3-yl][4-[2-(1-piperidinyl)ethoxyl]-phenyl]methanono hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem, 1984;27:1057-66.
27. Draper MW, Flowers DE, Neild JA, Juster WJ, Zerbe RL. Antiestrogenic properties of raloxifene. Pharmacology. 1995;50:209-17.
28. Black LJ, Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothiophene derived antiestrogon. Life Sci. 1983;32:1031-6.
29. Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY139481HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 1994;93:63-9.
30. Turner CH, Sato M, Bryant HU. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology. 1994;135:2001-5.
31. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCI: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 1996; 11:835-42.
32. Eppenberger U, Wosikowski K, Kung W. Pharmacologic and biological properties of droloxifene, a new antiestrogen. Am J Clin Oncol. 1991;14:S5-14.
33. Chen KH, Ke ZH, Jee WSS, et al. Droloxifene prevents ovariectomy-induced bone loss in tibiae and femora of aged female reats: a dual-energy x-ray absorptiometric and histomorphometric study. J Bone Miner Res. 1995;10:1256-62.
34. Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology. 1995;136:2435-41.
35. Shore RM, Chesney RW, Mazess RB, et al. Bone mineral status in growth hormone deficiency. J Pediatr. 1980;96:393-6.
36. Kaufman JM, Taelman P, Vermeulen A, Vandeweghe M. Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. J Clin Endocrinol Metab. 1993;74:118-23.
37. Demuinck Keizer-Schrama S, Rikken B, Wynne HJ et al. Dose-response study of biosynthetic hGH in GH deficient children. J Clin Endocrinol Metab. 1992;74:898-905.
38. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990;323;1-6.
39. Brixen K, Nielsen HK, Mosekilde L, Flyvbjerg A. A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers. J Bone Miner Res. 1990; 5:609-18.
40. Kelijman M. Age-related alterations of the GH/IGF-I axis. J Am Geriatr Soc. 1991;39:295-307.
41. Rosen CJ, Donahue LR, Hunter SJ. Age-related changes in insulin-like growth factor binding proteins. J Clin Endocrinol Metab. 1990;71:575-9.
42. Johansson AG, Lindh E, Ljunghall S. Insulin-like growth factor stimulates bone turnover in osteoporosis. Lancet. 1992;339:1619.
43. Aloia JF, Zanz I, Ellis K, et al. Effects of GH in osteoporosis. J Clin Endocrinol Metab. 1976;43:992-9.
44. Aloia JF, Vaswani A, Meunier PJ, et al. Coherence treatment of postmenopausal osteoporosis with GH and calcitonin. Calcif Tissue Int. 1987;40:253-9.
45. Johannson AG, Lindh E, Blwm WF, Kolleup G, Sorensen OH, Ljunghall S. Effects of short term treatment with IGF-1 and GH on markers of bone metabolism in idiopathic osteoporosis (abstract). J Bone Miner Res. 1994;9:S328.
46. Eriksen EF, Melsen F, Mosekilde L. Drug Therapy: formation-stimulating regimens. In: Osteoporosis: Etiology, Diagnosis and Management. Philadelphia: Lippincott-Raven; 1995:403-34.
47. Ebeling PR, Jones JD, O'Fallon WM, Janes CH, Riggs BL. Short term effects of recombinant human insulin-like growth factor I on bone turnover in normal women. J Clin Endocrinol Metab. 1993;77:1384-7.
48. Mohan S, Bautista CM, Wergedal J. Baylink DJ. Isolation of an inhibitory insulin-like growth factor (IGF) binding protein from bone cell-conditioned medium: a potential local regulator of IGF action. Proc Natl Acad Sci. 1989;86:8338- 42.
49. Narusawa K, Nakamura T, Suzuki K, et al. The effects of recombinant human insulin-like growth factor (rhIFG)-1 and rh IFG-1/IGF binding protein-3 administration on rat osteopenia induced by ovariectomy with concomitant bilateral sciatic neurectomy. J Bone Miner Res. 1995;10:1853- 64.
50. Havsteen B. Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol. 1983;32: 1141-8.
51. Yamazaki I. Effect of ipriflavone on the response of uterus and thyroid to estrogen. Life Sci, 1986;38:757-64.
52. Melis GB, Paoletti AM, Cagnacci A, et al. Lack of any estrogenic effect, of ipriflavone in postmenupausal women. J Endocrinol Invest. 1992;15:755-61.
53. Brandi ML. Flavonoids: Biochemical effects and therapeutic applications. Bone Miner. 1992;19:S3-14.
54. Reginster JY. Ipriflavone: Pharmacological properties and usefulness in postmenopausal osteoporosis. Bone Miner. 1993;23:223-32.
55. Morita I, Sakaguchi K, Kurachi T, Murota S. Ipriflavone inhibits murine osteoclast formation in vitro. Calcif Tissue Int. 1992;51(Suppl. 1):S7-10.
56. Bonucci E, Silvestrini G, Ballanti P, et al. Cytological and ultrastructural investigation on osteoblastic and preosteoclastic cells grown in vitro in the presence of ipriflavone: preliminary results. Bone Miner. 1992;19:S15-25.
57. Albanese CV, Cudd E, MacIntyre I. Effect of Ipriflavone on the isolated osteoclast. In: The First International Symposium on Osteoporosis and Metabolic Bone Diseases. London: International Academic Publishers; 1992:283.
58. Benvenuti S, Tanini A, Frediani U, et al. Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line. J Bone Miner Res. 1991;6:987-95.
59. Bonucci E, Ballanti P, Martelli A, et al. Ipriflavone inhibits osteoclast differentiation in parathyroid transplanted parietal bone of rats. Calcif Tissue Int. 1992;50:314-9.
60. Civitelli R, Abbasi-Jarhomi SH, Halstead LR, Dimarogonas A, Ipriflavone improves bone density and biomechanical properties of adult male rat bones Calcif Tissue Int. 1995;56:215-9.
61. Gambacciani M. Ipriflavone prevents the increase of bone turnover and the loss of bone mass in pharmacological menopause by GnRH-A (abstract). Osteoporos Int. 1996;6:317.
62. Gambacciani M, Spinetti A, Cappagli B, et al. Effects of ipriflavoine administration on bone mass and metabolism in ovariectomized women. J Endocrinol Invest. 1993; 16:333-7.
63. Agnusdei D, Gennari C, Bufalino L. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and a new, non-hormonal, bone active drug. Osteoporos Int. 1995;5:462-6
64. Agnusdei D, Adami S, Cervetti R, et al. Effects of Ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis. Bone Miner. 1992;19:S43-48.
65. Valente M, Bufalino L, Castiglione GN, et al. Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass. Calcif Tissue Int. 1994;54:377-80.
66. Passeri M, Biondi M, Costi D, et al. Effects of 2-year therapy with ipriflavone in elderly women with established osteoporosis. Italian Journal of Mineral and Electrolyte Metabolites. 1995;9:137-44.
67. Reginster JY. On behalf of the Group for the Respect of Ethics and Excellence in Science: Recommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis. Calcif Tissue Int. 1995; 57:247-50.
68. Reginster JY, Roux C, Riis BJ. Design for IMEFS (Ipriflavone Multicentre European Fracture Study) (abstract). Osteoporos Int. 1996;6:318.
69. Riggs M, Melton LJ. Involutional osteoporosis. N Engl J Med. 1986;314:1676-84.
70. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev. 1993;14:690-709.
71. Pugsley LI, Selye H. The histological changes in the bone responsible for the action of parathyroid hormone on the calcium metabolism of the rat. J Physiol. 1993;79:113-7.
72. Podbesek R, Edouard C, Meunier PJ, et al. Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds. Endocrinology. 1983; 112:1000-5.
73. Reeve J. PTH: A future role in the management of osteoporosis? J Bone Miner Res. 1996;11:440-5.
74. Canalis E, McCarthy TL, CCentrellaM. Differential effects of continuous and transient treatment with parathyroid hormone related peptide (PTHrP) on bone collagen synthesis. Endocrinology. 1990;126:1806-12.
75. Sogaard CH, Wronski TJ, McOsker JE, Mosekilde L. The positive effect of parathyroid hormone on femoral neck hone strength in ovariectomized rats is more pronounced than that of estrogen or bisphosphonates. Endocrinology. 1994;134:650-7
76. Mosekilde L, Sogaard CH, McOsker JE, Wronski TJ. PTH has a more pronounced effect on vertebral bone mass and biomechanical competence than antiresorptive agents (estrogen and bisphosphonate) - Assessed in sexually mature, ovariectomized rats. Bone. 1994;15:401-8.
77. Ejersted C, Andreassen, TT, Nilsson MHL, Oxlund H. Human parathyroid hormone (1-34) increases bone formation and strength of cortical bone in aged rats. Eur J Endocrinol. 1994;130:201-7.
78. Reeve J, Arlot ME, Price TR, et al. Periodic courses of human 1-34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodeling in spinal osteoporosis. Eur J Clin Invest, 1987;17:421-8.
79. Slovik DM, Neer RM, Potts JT. Short-term effects of synthetic human parathyroid hormone (1-34) administration on bone mineral metabolism in osteoporotic patients. J Clin Invest. 1981;68:1261-71.
80. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. New Engl J Med. 1994;331:1618-23.
81. Lindsay R, Cosman F, Shen V, Nieves J, Dempster DW. Bone mass increments induced by PTH treatment can be maintained by estrogen (abstract). J Bone Miner Res. 1995;10:S200.
82. Hodsman A, Fraher L, Adachi J. A clinical trial of cyclical clodronate as maintenance therapy following withdrawal of parathyroid hormone in the treatment of postmenopausal osteoporosis. J Bone Miner Res. 1995;10:S200.
83. Cohen FE, Strewler GJ, Bradley S, et al. Analogs of parathyroid hormone modified at positions 3 and 6. J Biol Chem. 1991;266:1997-2004.
84. Lane NE, Kimmel DB, Nilsson MHL, et al. Bone-selective analogs of human PTH (1-34) increase bone formation in an ovariectomized rat model. J Bone Miner Res. 1996;11:614-25.
85. Shorr E, Carter AC. The usefulness of strontium as an adjuvant to calcium in the remineralization of the skeleton in osteoporosis in man. Bull Hosp Jt Dis. 1952;13:59-66.
86. Marie PJ, Garba MT, Hott M, Miravet L. Effect of low doses of stable strontium on bone metabolism in rats. Miner Electrolyte Metab. 1985;11:5-13.
87. Marie PJ, Hott M. Short-term effects of fluoride and strontium on bone formation and resorption in the mouse. Metabolism. 1986;35:547-51.
88. Grynpas MD, Hamilton E, Chewng R, et al. Strontium increases vertebral bone volume in rats at a low close that does not induce detectable mineralization defect. Bone. 1996;18:253-9.
89. Boivin G, Deloffre P, Perrat B, et al. Strontium (Sr) distribution and interreactions with bone mineral in male monkey iliac bone after strontium salt (S12911) administration (abstract), Osteoporos Int. 1996;6:S251.
90. Ammann P, Rizzoli R, Deloffre P, Tsouderos Y, Meyer JM, Bonjour JP. The increase in vertebral bone mass induced in intact rats by long-term administration of the strontium salt S-12911 is directly correlated with vertebral bone strength (abstract). Osteoporos Int. 1996;6:S259.
91. Meunier PJ, Slosman D, Delmas PD, et al. The strontium salt S-12911: a new candidate for the treatment of osteoporosis (abstract). Osteoporos Int. 1996;6:S241.
92. Saltman PD, Strause LG. The role of trace minerals in osteoporosis. J Am Coll Nutr. 1993;12:384-9.
93. Reginster JY, Strause LG, Saltman P, Franchimont P, Trace elements and postmenopausal osteoporosis: a preliminary study of decreased serum manganese. Medicine Science Research. 1988;16:337-8.
94. Biquet I, Collette J, Dauphin JF, et al. Prevention of postmenopausal bone loss by administration of boron. Osteoporos Int. 1996;6:249.
95. Keeting PE, Oursler MJ, Wiegand KE, Bonde SK, Spelsberg TC, Riggs BL. Zeolite A increases proliferation, differentiation, and transforming growth factors beta production in normal adult human osteoblast-like cells in vitro. J Bone Miner Res. 1992;7:1281-9.
96. Franchimont N, Franchimont P, Caspar S, Reginster JY. Organic silicon decreases interleukin 6 but not leukemia inhibiting factor production in human osteoblast like cells in vitro (abstract). Bone. 1995;16:S226.
97. Wasnich RD, Benfante RJ, Yano K, et al. Thiazide effect on the mineral content of bone. N Engl J Med. 1983; 309:344-7.
98. Ray WA, Downey W, Griffin MR, et al. Long term use of thiazide diuretics and risk of hip fracture. Lancet. 1989; 1:687-90.
99. Lacroix AZ, Wienpahl J, White LR, et al. Long term use of thiazide diuretics agents and the incidence of hip fracture. N Engl J Med. 1990;322:286-90.
100. Heidrich FE, Stergachis A, Gross KM. Diuretic drug use and the risk of hip fracture. Ann Intern Med. 1991;115:1- 6.
101. Wasnich RD, Davis JW, He YF, Petrovich H, Ross PD. A randomized, double-masked, placebo-controlled trial of chlorthalidone and bone loss in elderly women. Osteoporos Int. 1995;5:247-51.
102. Raisz LG, Pilbeam CC, Fall PM. Prostaglandins: Mechanisms of action and regulation of production in bone. Osteoporos Int. 1993;136:136-40.
103. Bauer DC, Orwoll ES, Fox KM, et al. Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. J Bone Miner Res. 1996;11:29-35.
104. Fisher JE, Caufield MP, Sato M, et al. Inhibition of osteoclastic bone resorption in vivo by echistatin, an arginyl-glycyl-aspartyl (RGD)-containing protein. Endocrinology. 1993;132:1411-3.
105. Sato M, Sardana MK, Grasser WA, et al. Echistatin is a potent inhibitor of bone resorption in culture. J Cell Biol. 1990;111:1714-23.
106. Oursler MJ, Spelsberg TC. Echistatin, a potential new drug for osteoporosis. Endocrinology. 1993;132:939-40.
107. Kasten TP, Collin-Osdoby P, Patel N, et al. Potentiation of osteoclastic bone resorbing activity by inhibition of nitric oxide synthase. Proc Natl Acad Sci. 1994;91:3569-73.
108. MacIntyre I, Zaidi M, Towhidul AASM, et al. Osteoclast inhibition: An action of nitric oxide not mediated by cyclic GMP. Proc Natl Acad Sci. 1991;88:2936-40.
109. Ralston SH, Ho LP, Helfrich MH, et al. Nitric oxide: a cytokine-induced regulator of bone resorption. J. Bone Miner Res. 1995;10:1040-9.
110. Wimalawansa SJ, De Marco G, Gangula P, Yallampalli C. Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone. 1996;18:301-4.
111. Lauritzen JB, Petersen MM, Lund B. Effect of external hip protectors on hip fractures. Lancet. 1993;341:11-3.